Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 65 clinical trials
Featured trial
TOL2506A: A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Period of 48 weeks, and an End of Study Visit (Visit 8, Week 48). Eligible subjects will enter into the Treatment Period in 1 of 2 groups: those who will receive tamoxifen concurrently with TOL2506 or

letrozole
her2/neu-negative breast cancer
hormone therapy
estradiol
anastrozole
  • 0 views
  • 07 Jan, 2022
  • 1 location
Featured trial
Do you suffer from Hemorrhoids?

Do you suffer from Hemorrhoids?

  • 1549 views
  • 25 Mar, 2021
  • 1 location
Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer

This clinical trial is designed to be a multi-center prospective, parallel-controlled Phase III clinical study. In this study, the efficacy of tamoxifen versus toremifene shall be compared in

neutrophil count
estrogen
cancer
adjuvant chemotherapy
estrogen receptor
  • 28 views
  • 21 Jan, 2021
  • 20 locations
Tamoxifen Therapy for Myotubular Myopathy

This is a phase 1 / 2, randomized, double-blinded, single cross-over study, with a washout period between treatment regimens, to test the efficacy and safety of tamoxifen therapy to improve

  • 0 views
  • 04 Jul, 2021
  • 4 locations
Study of Intravaginal Tamoxifen in PostMenopausal Women With VVA (DARE-VVA1)

The purpose of the study is to study the safety, PK and PD of Intravaginal Tamoxifen on postmenopausal women with vulvar vaginal atrophy.

Accepts healthy volunteers
  • 0 views
  • 26 May, 2022
  • 2 locations
Tamoxifen in Treating Patients With Metastatic Bladder Cancer That Did Not Respond to Previous Chemotherapy

RATIONALE: Tamoxifen may slow the growth of tumor cells and may be an effective treatment for patients with metastatic bladder cancer that did not respond to previous chemotherapy

tumor cells
  • 34 views
  • 07 Nov, 2020
  • 1 location
A Study of Lerociclib in Participants With Advanced Breast Cancer

first line endocrine therapy such as tamoxifen, anastrozole, or letrozole (2L population). All premenopausal or perimenopausal female participants, and all male participants, must be receiving goserelin

  • 0 views
  • 26 May, 2022
  • 4 locations
Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers

Pilot study to test feasibility of 6 months of bazedoxifene (BZA) plus conjugated estrogens (CE) to modulate breast MRI parameters.

Accepts healthy volunteers
  • 0 views
  • 26 Mar, 2022
  • 1 location
Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women (ASPAIT)

or metastatic lymph nodes randomized to ovarian function suppression (OFS) plus aromatase inhibitors or OFS plus tamoxifen as adjuvant endocrine therapy, and explore the differences of curative

hormone therapy
immunostimulant
immunohistochemistry
aromatase inhibitor
adjuvant chemotherapy
  • 12 views
  • 23 Feb, 2022
  • 11 locations
Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ

, enrolling high-risk and low-risk clinicopathologic features of DCIS, demonstrated that a benefit of tamoxifen in terms of reducing the IBTR is observed in the BCS alone group but not found in the BCS plus

mammogram
radiotherapy to breast
estrogen
cancer
estrogen receptor
  • 13 views
  • 14 Feb, 2022
  • 1 location